GlassScriptPhysician profile
David A Hale
NPI 1952523375
$5,576.73
in general payments reported to CMS, 2019-2025
53 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,318 · 2020: $458 · 2021: $50.99 · 2022: $406 · 2023: $1,141 · 2024: $1,203.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,244 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.80 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $479.87 | 2019-2024 | Briviact, Rystiggo |
| Biogen, INC. | $418.33 | 2019-2024 | Tysabri, Vumerity, Avonex |
| Abbvie INC. | $317.55 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $299.63 | 2019-2023 | |
| Pfizer INC. | $283.26 | 2019-2024 | |
| Eisai INC. | $282.05 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $250.86 | 2019-2024 | Ultomiris |
| Mdd US Operations, LLC | $242.54 | 2019-2024 | Gocovri |
| Genzyme Corporation | $178.31 | 2019-2020 | |
| Allergan, INC. | $165.85 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $140.81 | 2019-2024 | Ingrezza, Ongentys |
| Celgene Corporation | $131.44 | 2022-2024 | Zeposia |
| Upsher-Smith Laboratories LLC | $126.63 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.18 | 2022 | |
| Amgen INC. | $122.94 | 2019-2023 | Aimovig |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.